Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Rentokil Initial highlights 'challenging' year as profits fall

(Sharecast News) - Rentokil Initial reported a drop in full-year profit on Thursday, citing a "challenging" year and a weaker performance in North America. Full-year group adjusted pre-tax profit fell 8.1% to £703m on revenue of £5.4bn, up 1.1% on the previous year.

Adjusted operating profit fell 4.2% during the year to £860m, impacted by the company's performance in North America. Rentokil said that as stated in its trading update in September, in North America there was a drop-through impact on profit from weaker-than-expected organic revenue growth and from significant in-year cost investments to drive revenue.

This resulted in a 130 basis points drop year-on-year in group adjusted operating margin to 15.4%.

Chief executive Andy Ransom said: "2024 was a challenging year for the group, with lower profits and margins, delivered in line with our trading update in September. Good growth in the international business (organic revenue growth 4.7%) was held back by the performance in North America (organic revenue growth 1.5%).

"Our sales and marketing initiatives to drive organic growth require further refinement to deliver the required improvements in overall lead generation and sales conversion, which will be a key focus in 2025. To address this, our revised branding strategy will see the national focus for the Rentokil and Terminix brands supplemented by additional prominence for our nine main regional brands.

"Alongside this, we will use insights from our promising satellite branch pilot to optimise the branch network size. We now expect that the end state branch network (including satellites) is likely to exceed 500 locations. Post integration we expect to generate both market beating growth and considerable cost efficiencies, with North American margins exceeding 20%."

Rentokil said it was still on track to achieve FY 2025 results in line with market expectations, despite first-quarter year-to-date growth in North America having been held back, mainly due to continued weak lead generation.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.